Randomized, Controlled Biomarker Study Evaluating the Anti-Angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel.

Trial Profile

Randomized, Controlled Biomarker Study Evaluating the Anti-Angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Sunitinib (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 16 Nov 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 17 Aug 2010 Planned end date changed from Jun 2010 to Jul 2011 as reported by ClinicalTrials.gov.
    • 04 Jun 2010 Interim results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top